Published • loading... • Updated
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Ad
Dr. Bing Hou will oversee Drug Discovery, Translational Medicine and CMC as Antengene expands a pipeline that includes 32 IND approvals in the U.S. and Asia.
- On Tuesday, Antengene Corporation Limited appointed Dr. Bing Hou as Chief Scientific Officer, reporting directly to Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene.
- Hou previously served as Vice President and Head of Discovery Science & Translational Medicine since joining Antengene in 2019, where he built the discovery organization and advanced internal programs into clinical development.
- Under his leadership, Antengene advanced the proprietary AnTenGager TCE 2.0 platform featuring "2+1" bivalent binding, and Hou has filed more than 40 patent applications for novel therapeutics.
- Hou will lead efforts across Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls, focusing on building a pipeline of next-generation therapeutic candidates with transformational potential.
- Antengene has obtained 32 investigational new drug approvals in the U.S. and Asia to date, alongside new drug application approvals in 10 Asia Pacific markets, supporting its global commercial-stage operations.
Insights by Ground AI
33 Articles
33 Articles
keenesentinel.com+31 Reposted by 31 other sources
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
SHANGHAI and HONG KONG, May 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies…
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Ad
SHANGHAI and HONG KONG, May 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing
·New York, United States
Read Full ArticleCoverage Details
Total News Sources33
Leaning Left7Leaning Right3Center8Last UpdatedBias Distribution44% Center
Bias Distribution
- 44% of the sources are Center
44% Center
L 39%
C 44%
R 17%
Factuality
To view factuality data please Upgrade to Premium
